Celularity Inc. Share Price & Technical Analysis
CELU · $0.90 (+3.45%)
Healthcare / Biotechnology
$0.90
+3.45%
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBa…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-10% return in May, 23% avg return in past 3 year May month.
-23% return in 2026, -33% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 9% | 0% | 8% | -31% | -10% | – | – | – | – | – | – | – | -23% |
| 25 | -5% | -43% | 55% | -12% | 40% | -9% | 65% | 18% | -32% | -5% | 5% | -45% | 33% |
| 24 | 52% | -12% | 41% | -43% | 3% | 0% | -3% | -3% | 3% | -50% | 33% | 5% | 26% |
| 23 | -31% | -21% | -11% | -6% | 25% | -32% | -27% | -24% | -35% | 0% | -9% | 14% | -158% |
| 22 | -12% | 60% | 20% | 34% | -18% | -64% | -7% | -13% | -13% | 0% | -27% | -29% | -69% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$22.00M
P/E ratio
—
52W high
$4.35
52W low
$0.71
Volume
61,322
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Celularity Inc. share price today?
- Celularity Inc. (CELU) last traded around $0.90 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CELU have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CELU. Download the app for real-time alerts.
- How can I analyze Celularity Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.